Dimensional Fund Advisors’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-1,481,405
Closed -$55.8M 3518
2021
Q1
$55.8M Sell
1,481,405
-62,375
-4% -$1.56M 0.02% 1353
2020
Q4
$26.3M Sell
1,543,780
-38,790
-2% -$486K 0.01% 1834
2020
Q3
$7.44M Sell
1,582,570
-88,245
-5% -$448K ﹤0.01% 2330
2020
Q2
$10.2M Sell
1,670,815
-132,403
-7% -$545K ﹤0.01% 2196
2020
Q1
$4.09M Buy
1,803,218
+103,863
+6% +$441K ﹤0.01% 2486
2019
Q4
$7.8M Sell
1,699,355
-26,697
-2% -$106K ﹤0.01% 2445
2019
Q3
$6.69M Sell
1,726,052
-16,054
-0.9% -$88.1K ﹤0.01% 2498
2019
Q2
$10.5M Buy
1,742,106
+83,400
+5% +$797K ﹤0.01% 2379
2019
Q1
$22.2M Buy
1,658,706
+174,528
+12% +$1.99M 0.01% 1990
2018
Q4
$13.8M Buy
1,484,178
+71,001
+5% +$845K 0.01% 2188
2018
Q3
$19.7M Buy
1,413,177
+223,523
+19% +$3.32M 0.01% 2126
2018
Q2
$18.8M Buy
1,189,654
+147,904
+14% +$2.58M 0.01% 2133
2018
Q1
$17.9M Buy
1,041,750
+67,474
+7% +$1.32M 0.01% 2122
2017
Q4
$21.4M Buy
974,276
+102,779
+12% +$3.31M 0.01% 2038
2017
Q3
$35.7M Sell
871,497
-18,079
-2% -$568K 0.02% 1636
2017
Q2
$26.8M Sell
889,576
-43,834
-5% -$1.37M 0.01% 1830
2017
Q1
$33.7M Buy
933,410
+92,338
+11% +$4.07M 0.02% 1586
2016
Q4
$42.1M Buy
841,072
+93,211
+12% +$4.9M 0.02% 1318
2016
Q3
$39.3M Buy
747,861
+276,325
+59% +$13.2M 0.02% 1300
2016
Q2
$19.5M Buy
+471,536
New +$20.5M 0.01% 1865

Dimensional Fund Advisors's FPRX Position: Q2 2021 in Review

Dimensional Fund Advisors sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 1,481,405 shares — an estimated $55.8M sold.

Dimensional Fund Advisors first reported a position in FPRX in Q2 2016 and held it in 20 quarters. The position peaked at $55.8M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.

  • Dimensional Fund Advisors reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
  • Dimensional Fund Advisors sold 1,481,405 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $55.8M.
  • Dimensional Fund Advisors first reported a position in Five Prime Therapeutics, Inc. in Q2 2016 and held it in 20 quarters.
  • Dimensional Fund Advisors's Five Prime Therapeutics, Inc. position peaked at $55.8M in Q1 2021.
  • 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.

Based on Dimensional Fund Advisors's 13F filing for Q2 2021, filed 12 Aug 2021.